Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05667155 | Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma | unknown | Phase 1 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05698303 | A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 | 12 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY |
| 1 |
| Jan 26, 2023 |
| clinicaltrials |
| NCT05007418 | Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 54 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05266768 | Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002# | unknown | Phase 1 | 36 | Chunrui LiOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05135858 | Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma(METHOGLU) | unknown | Phase 1 | 18 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT04684472 | Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies | unknown | Phase 1 | 18 | Liqun ZouOTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT05549973 | Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 | 32 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT04688853 | A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients | unknown | Phase 1 | 26 | Gadeta B.V.INDUSTRY | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05528887 | Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies | unknown | Phase 1 | 10 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Sep 6, 2022 | clinicaltrials |
| NCT05498636 | SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression | unknown | Phase 1 / Phase 2 | 67 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT04935580 | Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients | unknown | Phase 1 / Phase 2 | 20 | Shanghai Changzheng HospitalOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05412329 | Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma | unknown | Phase 1 | 9 | Shanghai Changzheng HospitalOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT05453669 | Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL | unknown | Phase 1 | 12 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT04831658 | A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Mingzhi ZhangOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04058470 | Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 140 | Huiqiang HuangOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05325801 | A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 9 | Zhejiang UniversityOTHER | 0 | Apr 13, 2022 | clinicaltrials |
| NCT05003141 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | unknown | Phase 1 | 110 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics)INDUSTRY | 3 | Mar 28, 2022 | clinicaltrials |
| NCT02481310 | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT05052970 | Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM | unknown | Phase 1 | 60 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.INDUSTRY | 1 | Feb 1, 2022 | clinicaltrials |
| NCT05155215 | Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma | unknown | Phase 1 / Phase 2 | 68 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 0 | Dec 13, 2021 | clinicaltrials |
| NCT05150522 | B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT05143112 | Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT05066646 | A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)(FUMANBA-1) | unknown | Phase 1 / Phase 2 | 132 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 23, 2021 | clinicaltrials |
| NCT04818372 | Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma | unknown | Phase 1 | 87 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Nov 12, 2021 | clinicaltrials |
| NCT05039658 | Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) | unknown | Phase 1 | 50 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Sep 9, 2021 | clinicaltrials |
| NCT03720457 | Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. | unknown | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 31, 2021 | clinicaltrials |
| NCT05021770 | Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma | unknown | Phase 1 / Phase 2 | 29 | Huiqiang HuangOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT04984434 | Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 68 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Jul 30, 2021 | clinicaltrials |
| NCT04897477 | Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | May 21, 2021 | clinicaltrials |
| NCT03670173 | Safety and Efficacy Assessments of Osalmid in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 20 | Shanghai 10th People's HospitalOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT04891744 | Selinexor in Combination With Thalidomide and Dexamethasone in RRMM | unknown | Phase 1 / Phase 2 | 48 | Li ZhengOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT04887012 | Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL | unknown | Phase 1 | 25 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT03795597 | Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)(BuMelCarAuto) | unknown | Phase 1 / Phase 2 | 36 | Loyola UniversityOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT04476459 | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL | unknown | Phase 1 / Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04796857 | Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL | unknown | Phase 1 / Phase 2 | 30 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04003168 | Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Mar 1, 2021 | clinicaltrials |
| NCT04762745 | The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04558853 | Clinical Study of Autologous Natural Killer Cells in Multiple Myeloma | unknown | Phase 1 | 12 | Karolinska University HospitalOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT03156101 | A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects | unknown | Phase 1 / Phase 2 | 24 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04296461 | Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma | unknown | Phase 1 | 20 | UWELL BiopharmaINDUSTRY | 1 | Jan 22, 2021 | clinicaltrials |
| NCT02772198 | T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies | unknown | Phase 1 / Phase 2 | 300 | Sheba Medical CenterOTHER_GOV | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03921879 | Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma | unknown | Phase 1 | 50 | Oncotartis, Inc.INDUSTRY | 1 | Oct 23, 2020 | clinicaltrials |
| NCT03716856 | Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma | unknown | Phase 1 | 11 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03711864 | Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma | unknown | Phase 1 | 15 | Peking Union Medical College HospitalOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04537442 | Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT04486872 | An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection | unknown | Phase 1 | 18 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT04500431 | Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM | unknown | Phase 1 | 10 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT04500561 | YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial | unknown | Phase 1 / Phase 2 | 28 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Aug 5, 2020 | clinicaltrials |
| NCT04275583 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 17, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Feb 6, 2023source: clinicaltrials